Podcasts about Keynote

In this podcast , Brian, Tom and Matt Galsky discuss the B15 study data on neoadjuvant therapy for muscle invasive bladder cancer, focusing on the efficacy of EV Pembro compared to gem-cis. They explore event-free survival, overall survival, and the implications of treatment duration and individualization. The conversation also touches on the role of ctDNA in treatment decisions, alternative histologies, and the importance of neoadjuvant systemic therapy. The hosts conclude with reflections on future directions in bladder cancer treatment and the significance of ongoing studies.

“We keep iterating on an old construct—let's stop and start over. How do we want to do things differently? Let's get back to first principles.”KP ReddyEpisode Summary:In this special ElevateAEC 2025 edition of The Zweig Letter Podcast, we're sharing KP Reddy's keynote from the main stage—a straight-talk session about where innovation in AEC is actually heading. Drawing from real conversations with major owners, hands-on research, and his own experience as an engineer and investor, KP breaks down why the industry's current approach to innovation isn't cutting it—and what needs to change.He tackles the questions that matter: What do owners actually want? How can AI and agentic systems make a real difference? And what would a new master builder mindset look like today? This keynote delivers practical insights and honest challenges for AEC leaders ready to rethink how they approach business, technology, and client value.Key Takeaways:Owners Want Real Innovation, Not Lip Service: True innovation means solving problems in significantly better ways—not just adopting new technology for technology's sake. Owners are craving AEC partners who listen and deliver true value.Communication Gaps Hurt Everyone: Clients frequently feel like outsiders in the process, with their feedback often ignored. Successful firms will prioritize transparency, owner-centric approaches, and collaborative requirement gathering.Tech Is a Tool—Not the Solution: Despite years of BIM and other advancements, core challenges with cost, schedule, and quality persist. The next leap forward will come from integrating AI, agentic design, and robotics as part of service delivery—and from business models, not software alone.Business Model Reinvention Is Essential: Shifting away from headcount-driven metrics, AEC firms should explore skin-in-the-game approaches—like bonuses for outcomes, equity stakes, and public-private partnerships.Client and Product Manufacturers Must Both Change: Building-product innovators report frustration as AEC professionals and owners often resist new solutions. KP encourages the industry to break the cycle of “the way we've always done it” and fully explore prefabrication, modularity, and automation.All this and more on this episode of the Zweig Letter podcast.KP Reddy is the founder and CEO of Shadow Ventures and a recognized voice on innovation in architecture, engineering, and construction. With expertise spanning AI, robotics, and automation—plus his role as a lecturer at Georgia Tech—KP brings practical strategies that push the AEC industry forward.Links referenced in this episode:Shadow VenturesKP Reddy on LinkedIn"Creating the Intangible Enterprise" by KP ReddyZweig Group & ElevateAEC ConferenceLearn about the Zweig Letter and subscribe: https://thezweigletter.com/Connect with Randy Wilburn on LinkedInGet your FREE Subscription to the Zweig Letter Newsletter.Stay tuned for more enlightening content from the Zweig Letter podcast, and make sure to subscribe for regular updates!Other episodes you'll enjoy:Architecture with Heart - Carley ChastainFrom Specs to Stories with Cherise LakesideBridging Design and Construction with Dan CristAI Transforming AEC with KP ReddyConnect with Zweig Group:Instagram: Zweig GroupFacebook: Zweig GroupTwitter: Zweig GroupLinkedIn: Zweig GroupWebsite: Zweig Group

Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the evidence-based recommendations. They also comment on ongoing and recently presented trials that may impact future guidelines in this space. Read the full guideline, "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update" at www.asco.org/gastrointestinal-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02958      Timestamps ·       00:00 – 02:15 Introduction and Overview ·       02:16 - 08:20 First-line treatment for patients with pMMR/MSS, HER2-negative gastroesophageal adenocarcinoma ·       08:21 –10:29 First-line treatment for patients with pMMR/MSS, HER2-positive gastroesophageal adenocarcinoma ·       10:30 – 14:39 First-line treatment for patients with dMMR/MSI-H, gastroesophageal adenocarcinoma ·       14:40 – 18:03 First-line treatment for ESCC ·       18:04 – 22:04 Second- and third-line therapy for gastroesophageal adenocarcinoma and ESCC ·       22:05 – 24:38 Importance of guideline ·       24:39 – 27:45 Outstanding questions and future research   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.   My name is Brittany Harvey, and today I am interviewing Dr. Lakshmi Rajdev from the Icahn School of Medicine at Mount Sinai and Dr. Manish Shah from Weill Cornell Medicine, co-chairs on "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update." Thank you for being here today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you for having us. It is wonderful. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Rajdev and Dr. Shah, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Shah, I would like to start first with what prompted the update to this guideline, which was previously published in 2023, and what is the scope of this updated guideline? Dr. Manish Shah: Yes, terrific. So even in the last few years, the pace of drug development in gastroesophageal cancers has just been astounding. So, what prompted this guideline is actually the practice-changing results for a new biomarker, CLDN18.2 hat was based on the GLOW and SPOTLIGHT studies, as well as a practice-changing study in HER2-positive disease where we added pembrolizumab to trastuzumab and chemotherapy for tumors that are HER2-positive and PD-L1 CPS 1 or greater. And then there were also new studies and new approvals in esophageal squamous cell cancer that you will hear about as well. So there were several studies, overall more than 5,000 patients were reported on, and that led to several new therapies, new indications, and it really necessitated this guideline. Brittany Harvey: Excellent. It is great to hear about all of these exciting updates in this space. So then to next review the key recommendations of this guideline by clinical question that the expert panel addressed. So, Dr. Rajdev, what is the recommended first-line treatment for patients with proficient mismatch repair, microsatellite stable, HER2-negative gastroesophageal adenocarcinoma? Dr. Lakshmi Rajdev: Thank you for that question. So historically, we have sort of used fluoropyrimidine and platinum doublets, which yielded a survival of about one year. More recently, immunotherapy and targeted therapy options have improved outcomes in patients with advanced esophageal and gastric adenocarcinoma, as well as squamous cell carcinoma. Patients with gastric and GE junction adenocarcinoma have a high rate of actionable alterations, so it is imperative that physicians test the following biomarkers upfront so that it can help guide therapy. The markers recommended by the ASCO panel are HER2, MMR or MSI, CLDN18.2, and PD-L1. And also, it was recommended to use NGS if feasible in this patient population. HER2, as we know, is expressed in about 15% to 25% of patients; PD-L1 expression occurs in about 80% of patients; MSI-high, deficient MMR is present in about 5% to 8% of patients; and CLDN18.2 expression is present in about 40% of patients. There is, of course, biomarker overlap. About 13% to 22% of CLDN18.2 patients are also PD-L1 positive. For patients with pMMR or microsatellite stable HER2-negative disease with PD-L1 expression greater than 1 and absence of CLDN18.2, the panel recommended a first-line therapy with fluoropyrimidine and platinum-based therapy in combination with immunotherapy. These recommendations stem from large phase 3 trials, and the agents approved in the United States are pembrolizumab, nivolumab, and tislelizumab. It has been shown that immunotherapy benefit is greater in patients with higher PD-L1 expression, and it is not possible to comment on the individual PD-L1 cutoff scores and sort of identify the optimal PD-L1 cutoff score that sort of balances benefits and harms. But what is recommended is that immunotherapy-based treatments can be offered in patients with a CPS score of greater than 1. With regard to the choice of immunotherapy agents, that is pembrolizumab, nivolumab, or tislelizumab, these agents are considered to have similar efficacy, and the selection of an agent could be based on dosing schedule, cost considerations, toxicity, and the method of administration. Typically, clinicians should avoid withholding the start of chemotherapy while awaiting biomarker testing, depending on the clinical scenario. Now, for patients with pMMR microsatellite stable disease that is HER2-negative with PD-L1 expression less than 1 and positive CLDN18.2 expression, zolbetuximab-based treatments or in combination with chemotherapy is recommended, and this is based on two global phase III randomized controlled trials, the GLOW and the SPOTLIGHT. And across both studies, the hazard ratio for the overall survival was 0.78, and similarly, there was also an improvement in progression-free survival favoring the zolbetuximab group compared to the chemotherapy group alone. An important note is that nausea, vomiting is commonly associated with zolbetuximab-based treatments, and the panel recommended prophylactic antiemetics, adjusting zolbetuximab infusion rates, pausing infusion temporarily, using non-prophylactic antiemetics, and hydration intravenously prior to discontinuation of zolbetuximab-based chemotherapy. So effective handling of the GI-related symptoms with zolbetuximab is recommended prior to discontinuation of therapy. Now, for patients with pMMR microsatellite stable HER2-negative gastric, GE junction adenocarcinoma with PD-L1 expression greater than 1 and CLDN18.2 positivity, the ones with the dual expression with CLDN18.2 as well as PD-L1 chemotherapy, the choice of therapy can be based on the degree of PD-L1 expression, the toxicity profile, the burden of symptoms, and the anticipated improvement in symptoms associated with response to treatment, the patient comorbidities, the prior medical and treatment history. So this decision needs to be made on a case-by-case basis, and these are some of the factors that we suggested that could potentially influence the choice of therapy. For patients with pMMR microsatellite stable disease that is HER2-negative and a PD-L1 expression less than 1 and an absence of CLDN18.2 expression, first-line therapy with fluoropyrimidine and platinum-based chemotherapy is recommended. So you can see we have segmented out patients based on PD-L1 expression, pMMR and microsatellite stable disease expression, and also based on CLDN expression. Brittany Harvey: Absolutely. And that first point you noted, I think is really important, that biomarker testing is really critical for treatment decision-making in this space. So then the next subgroup of patients that the panel looked at, Dr. Shah, what first-line therapy is recommended for patients with proficient mismatch repair, microsatellite stable, HER2-positive gastroesophageal adenocarcinoma? Dr. Manish Shah: So this was an update from a few years ago. So we have known for 15 years now that if you are HER2-positive, you should get trastuzumab plus chemotherapy. That was based on the ToGA trial. And the update now is based on a trial called KEYNOTE-811, where it examined the addition of pembrolizumab to trastuzumab and chemotherapy versus trastuzumab and chemotherapy, and there was a progression-free and overall survival benefit. And again, here, the biomarkers are important. If your CPS PD-L1 is less than 1, we would not recommend Pembrolizumab in that setting, so you would still get trastuzumab and chemotherapy. But if it is 1 or greater, the PD-L1 CPS score, then we do recommend pembrolizumab unless there is a contraindication to immunotherapy. The take-home message really is from the onset of diagnosis, please check your biomarkers. And I will just, it is worth repeating, it is important to check your PD-L1 status, HER2 status, mismatch repair status, and CLDN18.2 status. And then the optimal therapy, and it is outlined in the publication, is really biomarker-driven. We know that if we are able to hit the target that is overexpressed, we are going to have a better outcome. And Dr. Rajdev did mention where there is overlap, there can be a lack of data, and that is where we are with both PD-L1 positive and CLDN positive. Here we do have data in HER2-positive cases where if you are both HER2-positive and PD-L1 positive, you would combine trastuzumab and pembrolizumab for the best outcomes. Brittany Harvey: Understood. I really appreciate you detailing what is most important for each individual biomarker combination that patients may have. So then following that, Dr. Rajdev, what does the expert panel recommend for first-line treatment for patients with esophageal squamous cell carcinoma that is not amenable to definitive chemoradiation? Dr. Lakshmi Rajdev: There are three phase III randomized clinical trials that have influenced practice in patients with esophageal squamous cell carcinoma examining the benefit of immunotherapy in this patient population. The RATIONALE-306 was a randomized trial of tislelizumab plus chemotherapy with platinum and fluoropyrimidine or paclitaxel versus placebo with chemotherapy. And then you have the KEYNOTE-590, which compared pembrolizumab plus chemotherapy versus chemotherapy alone. And then you have CheckMate-648, which included comparisons of nivolumab plus chemotherapy versus nivolumab plus ipilimumab or chemotherapy. And the primary endpoints for these studies were overall survival, and they did look at subgroups with PD-L1 expression. They used TPS score greater than 1% in CheckMate-648 and PD-L1 CPS greater than 10 in KEYNOTE-590. The bottom line is that the overall hazard ratio for overall survival across this patient population was 0.72. So clearly, there is benefit in patients that express PD-L1 CPS greater than 1 for benefit for the addition of immunotherapy. Now, the benefit again in patients with a PD-L1 expression less than 1 remains limited, and so the panel has made a recommendation for using immunotherapy in combination with platinum-based chemotherapy in patients with a PD-L1 greater than 1. Again, we know that it is hard to make recommendations on what PD-L1 cutoffs are recommended in this patient population, meaning that should it be limited to patients with a PD-L1 of 1 to 4 or greater than 10? I think that the general consensus that has been gleaned from the data is that the higher the PD-L1 expression, the greater the benefit. I do want to comment on another option that is available in patients with squamous cell carcinoma compared to adenocarcinoma, and that is the combination of nivolumab and ipilimumab. Now, in CheckMate-648, nivolumab with ipilimumab was also recommended as a treatment option in patients that have a PD-L1 score of greater than 1. There was a survival benefit demonstrated with this combination compared to chemotherapy alone. And an important observation in this study is that, although there was a slightly increased rate in early death, but there was really no significant difference in PFS and OS compared to chemotherapy alone. Importantly, the treatment appeared to be pretty well tolerated by the study population. There was a notable difference in the objective response rate, which was 35% in the nivolumab plus ipilimumab group compared to patients receiving nivolumab and chemotherapy, where it was 53%. So superiority is, so the importance of chemotherapy in patients with esophageal squamous cell carcinoma is to be noted. However, there is no difference in overall survival and progression-free survival when using the combination of nivolumab and ipilimumab, and thus it affords a chemotherapy-free option for this patient population with esophageal squamous cell carcinoma and a CPS with a score of greater than 1. Brittany Harvey: Understood. I appreciate you reviewing the evidence underpinning those recommendations as well. So then the next patient population that the guideline panel addressed, what first-line therapy is recommended for patients with deficient mismatch repair, microsatellite instability-high, gastroesophageal adenocarcinoma or esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: The rate of MSI-high expression is about 3% to 7% across different studies. Now, the KEYNOTE-158 was a tumor-agnostic study in patients with non-colorectal cancers, and again, the problem with the MSI-high population, given that it is so rare, the numbers in the individual studies are fairly small. But consistent outcomes do emerge, indicating high response to immunotherapy. So in KEYNOTE-158, a response rate of about 46% was noted. The number of patients was small, it was about 24. In CheckMate-649, which is a study of chemotherapy plus or minus nivolumab in patients with advanced gastric adenocarcinoma, there was again a very small number of patients, and patients that were MSI-high or deficient MMR did experience substantial benefits with the addition of immunotherapy, with hazard ratios in the order of about 0.38. In KEYNOTE-062, again, it was a very small number of patients, again about 6% or so, and similar to CheckMate-649, a substantial benefit was noted in combination with chemotherapy, but also there were benefits noted with pembrolizumab alone. The RATIONALE-305 again was a study of tislelizumab in combination with chemotherapy and similarly showed benefits to the combination of chemotherapy plus immunotherapy in this patient population. I think that we are all aware of the dramatic benefits of immunotherapy in this particular subset of patients, deficient MMR MSI-high, and also we have seen in CheckMate-649 they did have a subset of patients that received nivolumab and ipilimumab. And in this patient population, they noted unstratified hazard ratio of 0.28. So I think that the overall consensus is that immunotherapy is a very important treatment modality in patients with deficient MMR MSI-high disease, given that a lot of the trials in gastroesophageal adenocarcinoma have utilized chemotherapy-based options, that is certainly a recommendation of the panel to use chemotherapy in combination with immunotherapy. However, on a case-by-case basis, the panel recommended immunotherapy alone as well, and given the high response rates noted in trials across different diseases as well as noted in this disease as well. Brittany Harvey: Certainly. And I appreciate you both for reviewing these first-line recommendations. So moving to later lines of therapy, Dr. Rajdev, what recommendations did the expert panel make for second or third-line therapy for gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: So, I think that the RAINBOW trial that investigated the utility of the addition of ramucirumab as second-line therapy has been around since 2014, and those results have led to the addition of ramucirumab to taxane-based therapy in the second-line setting. Based on the utilization of oxaliplatin and platinum-based therapy in the front-line setting, there may be patients that have an underlying neuropathy, and so we wanted to really include treatment options for this patient population so that an agent that is less neurotoxic could also be recommended in combination with ramucirumab. The RAMIRIS trial is one such trial where ramucirumab was combined with FOLFIRI, and it demonstrated benefit in combination with ramucirumab. So we have listed that as a potential treatment option for patients in the second-line setting who may have an underlying neuropathy or even for whatever reason that based on the toxicity profile, that needs to be the preferred option by a physician, that recommendation is new from the older guidelines that we have. With regard to the utility of PD-1 inhibitors, there really has been no benefit noted in the second-line setting with regard to overall survival or progression-free survival, so no recommendation is made for that option. I think an important study that has been recently presented is the DESTINY-Gastric04 trial, which really has been practice-changing and has led to the recommendation for trastuzumab deruxtecan in patients that have HER2-positive metastatic gastric or GE junction adenocarcinoma. Now, this is a phase III trial in patients who retained HER2-positive disease after progressing on front-line trastuzumab-based treatments, and the comparator for this trial was trastuzumab deruxtecan versus ramucirumab plus paclitaxel. There was significant improvement and progression-free survival in patients that received trastuzumab deruxtecan. The patients that were excluded from the trial are patients that have pulmonary problems, interstitial lung disease; that is one of the toxicities of this particular agent, and close monitoring and prompt initiation of therapy such as glucocorticoid treatment in patients who develop this toxicity was also highlighted by the panel. So to summarize, the new guidelines highlight the possibility of FOLFIRI plus ramucirumab as a second-line option and then trastuzumab deruxtecan as a later-line option in patients that still retain HER2 expression. And that is very important because the trial did retest patients whether they expressed HER2. As we know, in a substantial number of patients, there is downregulation of HER2, and there is emerging data that the benefit for subsequent HER2-directed therapies is best noted in patients that still retain HER2 expression. Brittany Harvey: Great. So as our listeners have heard, there are many recommendations and new treatment options for advanced gastroesophageal cancer. Dr. Shah, earlier you highlighted the importance of biomarker testing, but I would like to hear in your view, what is the importance of this guideline and how will it impact both clinicians and patients with gastroesophageal carcinoma? Dr. Manish Shah: So as we have discussed throughout this podcast, the treatment for gastroesophageal cancer, both adenocarcinoma and squamous cell cancer, is increasingly complex, increasingly biomarker-driven. And I think the value of the guideline is to place all of that into context. So it provides the data for why certain biomarkers are important, what therapies should be indicated. Not only that, but if you are able to review the guideline, it provides the details of each of these studies and summarizes them in a meta-analysis fashion to sort of give you the context, because sometimes the individual studies can be maybe a little bit discordant or confusing and the guideline attempts to harmonize all that. And then also, I think the tables are very, very interesting because they give you actual numbers in terms of how many patients over a thousand would this benefit or how many patients over a thousand would this cause harm in terms of nausea, vomiting, or other things like that. So it gives you context for helping clinicians and patients weigh the potential benefits of the novel treatment strategies against the potential adverse events. And then finally, the guideline does also provide an algorithm that you are able to follow based on the biomarkers, and those are in figures 4 and 5. So I think overall, it is a very comprehensive guideline. It intends to make more manageable a very complex subject, and you know, I really encourage our listeners to review it after listening to the podcast. Dr. Lakshmi Rajdev: If I can add to that, I think that what is also really good about the guidelines is there are quick summaries. So if someone is busy in the clinic, of course, there is the opportunity to review the data supporting the guidelines in great depth in the manuscript, but what is also really good is that there are good summaries. In the event that you are very busy, you can easily identify what the recommendations should be for that particular patient based on these summaries. Brittany Harvey: Absolutely. Listeners are encouraged to review the full guideline, including those tables and figures that may be more helpful when they are looking for something quick to look at in the clinic as well. So, as you both mentioned, there have been a number of recent practice-changing trials in this area. So I imagine there is still a lot of ongoing research as well. So Dr. Shah, what are the outstanding questions regarding treatment options for patients with locally advanced unresectable, advanced, or metastatic gastroesophageal carcinoma? Dr. Manish Shah: I think we touched upon it a little bit. The guidelines are based on the data available, and they are primarily examining one novel therapy with chemotherapy in a specific biomarker population. But as you know, the biomarkers are not either/or; you are not either CLDN18.2 positive or PD-L1 positive. A portion of patients could have dual biomarkers, and you know, I think that we are generating data on how to manage those patients. At the recent GI Symposium in January this year, the ILUSTRO trial was presented by Dr. Shitara, which looked at combining zolbetuximab and chemotherapy with immunotherapy for dual-positive biomarkers, and that is leading to a phase III study that has begun to enroll. So unanswered questions are: how do we manage dual-positive biomarkers? The other thing that was mentioned is that the current data for mismatch repair deficiency involve chemotherapy plus immunotherapy. Only squamous cell cancer is there a study with a positive non-chemotherapy kind of backbone, that is CheckMate-648 that Dr. Rajdev mentioned. As we move forward, it will be good to get data on non-chemotherapy options in certain biomarker-positive populations. And then finally, another update, which is likely to be practice-changing, is the HERIZON-GEA-01 study that looked at zanidatamab, which is another biparatopic antibody that targets HER2, and that is likely to change practice. And as that data gets published, we may look to even do a rapid update for the current immunotherapy and targeted therapy guideline that is just being published. Dr. Lakshmi Rajdev: So, if I can add to that, there are numerous ADCs that look very interesting. There are bispecific antibodies; in fact, the zanidatamab is a bispecific antibody showing improved activity in patients with HER2-positive disease. So I think there are studies from Asia looking at CLDN CAR T-based therapies. So, I think that there are a lot of novel agents and a lot of excitement in the field. We know that the bemarituzumab study, unfortunately, the FGFR2 inhibitor failed to demonstrate any benefit, but I think that there are other agents that are being explored, so there are newer targets, newer agents, ADCs, bispecifics that could potentially change the field in the future. Brittany Harvey: Yes, we will look forward to the data to address these unanswered questions and new agents and inform future guideline updates. So, I would like to thank you both for all of your work to review the evidence here and update this important guideline, and for your time today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In dieser Episode von Kassenzone, moderiert von Karo und Alex, nehmen wir die Zuhörer mit auf eine spannende Reise durch die aktuellen Entwicklungen im E-Commerce-Sektor. Wir reflektieren über die ersten Events des Jahres 2026, die für uns eine wichtige Plattform darstellen, um wertvolle Einblicke zu gewinnen und mit der Community zu interagieren. Besondere Erwähnung finden die Teilnahme an der E-Commerce Expo in Berlin, wo wir zahlreiche interessante Kontakte knüpfen konnten, sowie die hochkarätige Keynote von Alex, die großes Interesse weckte. Ein zentrales Thema dieser Episode ist das Kassenzone-Meetup, das sich heute mit dem TikTok-Shop auseinandersetzt. Alex gibt uns einen Einblick in die Fragen, die er den Experten bei diesem Event stellen möchte, und wir sprechen darüber, wie TikTok auch für hochpreisige Produkte ein funktionierender Vertriebskanal sein könnte. Neben dem Fokus auf die Community und den Austausch von Ideen in den Meetups, bereiten wir uns auch auf zukünftig große Events wie die OMR und Data Unplugged vor, bei denen wir die Möglichkeit haben, noch intensivere Gespräche zu führen und wertvolle Erkenntnisse zu gewinnen. Wir steigen dann tief in die neuesten Zahlen des ECDB Global E-Commerce Compass 2026 ein. Wir analysieren, wie das globale E-Commerce-Wachstum in den letzten Jahren eine Phase der Normalisierung durchläuft. Die Wachstumsprognosen deuten auf eine Stabilisierung bei 7,8 Prozent für 2025 und eine beschleunigte Rate von 8,6 Prozent für 2026 hin. Wir stellen fest, dass der weltweite E-Commerce-Umsatz die 5 Billionen US-Dollar-Marke überschreiten wird, was die nachhaltige Relevanz des Online-Handels im Vergleich zum analogen Einzelhandel unterstreicht. Partner in der Folge: https://linktr.ee/kassenzone Community: https://kassenzone.de/discord Feedback zum Podcast? Mail an alex@kassenzone.de Disclaimer: https://www.kassenzone.de/disclaimer/ Kassenzone” wird vermarktet von Podstars by OMR. Du möchtest in “Kassenzone” werben? Dann https://podstars.de/kontakt/?utm_source=podcast&utm_campaign=shownotes_kassenzone Alexander Graf: https://www.linkedin.com/in/alexandergraf/ https://twitter.com/supergraf Youtube: https://www.youtube.com/c/KassenzoneDe/ Blog: https://www.kassenzone.de/ E-Commerce Buch 2019: https://amzn.eu/d/5Adc1ZH Plattformbuch 2024: https://amzn.eu/d/1tAk82E

The global credit market is worth $300 trillion and Michael Saylor believes digital credit will capture a massive share of it. In this keynote from Strategy World 2026, Saylor walks through the complete theory of digital credit from first principles: what Bitcoin is, why variable preferred equity is the longest-duration capital structure short of equity, and how STRC delivers double-digit yields with deferred tax treatment and principal protection. He also lays out the programmable future of digital money and digital yield, with ETFs, on-chain tokens, and bank accounts all being built on top of STRC as a foundation.

Join host Anne Bonney, CSP, as she chats with Cassandra Worthy about her journey from corporate leader to main stage Influence speaker. Get straight talk on the strategies, mindset, and frameworks that can help you bring lasting value to your clients and grow your speaking business.What you'll learn in this episode:* How Cassandra Worthy transitioned from corporate America to a career in speaking* The pivotal moment that inspired her "change enthusiasm" framework* Why building a practical, actionable framework sets speakers apart* What clients are really looking for now—partnership over performanceTop advice for speakers preparing for big stages and growing their network strategicallyBecome an NSA Member! https://nsaspeaker.org/join/#membership Attend Influence 2026! Register here: https://influence.nsaspeaker.org/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Presidential Task Force on Institutional Voice Draft Report  October 2025 Update  Please provide feedback on the report  Members of our community —  whether students, staff, faculty, or alumni — feel deeply about many local, national, and world events, but does that mean that a university should opine on such weighty matters? Or should the university sit back and allow the individual voices of the community rise to the surface? Can it do both? And when the university does speak, who speaks for the university? What principles should govern this decision of when and how often to speak?  Last year, Cornell University created the Presidential Task Force on Institutional Voice to examine these questions and issue recommendations to the community. A draft report was released to the Cornell community during the fall semester outlining principles and providing suggestions to guide how the president, provost, deans, academic departments, and others should approach this issue. The Task Force was co-chaired by Cornell Law School Dean Jens David Ohlin and Deputy Provost Avery August. In this Keynote, Dean Ohlin and the Professor Nelson Tebbe will discuss the Task Force's findings. What You'll Learn: How Cornell University is studying the issue of institutional voice The principles and guidelines recommended by Cornell's Presidential Task Force on Institutional Voice The various approaches that other universities have taken on this issue Follow eCornell on YouTube, Facebook, Instagram, LinkedIn, TikTok, and X.

In deze Deep Dive duiken we in de oude doos met Bart Mol van Satoshi Radio, het Crypto Journaal en Bitcoin Alpha. Hoe hebben de grote cryptoverhalen van vroeger de cryptowereld van nu gevormd? Om die vraag te beantwoorden kijken we terug naar de verwoede pogingen van de Winklevoss broers om een Bitcoin ETF uit te geven, de blockchainhype van 2017 toen alles en iedereen dacht dat blockchain de wereld ging veranderen en naar het Libra-project van Facebook. Ook de legendarische Bitconnect conferentie en de Terra/Luna Death Spiral passeren de revue. Alle verhalen vertellen iets over hoe we naar Bitcoin en crypto keken, hoe bedrijven en personen zich profileerden naar de buitenwereld en ook hoe het publiek omging met de hype die er soms rond crypto hangt. Sommige initiatieven strandden, andere inspireren bedrijven om bepalende stappen te maken die de wereld van het geld nog steeds vorm geven. We bespreken hypes, trends en alle te mooie beloftes van de afgelopen vijftien jaar in deze aflevering van de Deep Dive. Besproken in deze aflevering Keynote van Bart op Bitcoin Amsterdam Bart over de risico's van het 'Bitcoin als digitaal goud-narratief' in de Cryptocast De Instagrampagina van Veronique Over de podcast Cryptocurrency are here to stay. In deze wekelijkse podcast gidst Daniël Mol je door het belangrijkste cryptonieuws, langs hypes en trends, voor- en tegenstanders en winst en verlies. In het A-deel bespreken we het laatste nieuws en in het B-deel gaan we in gesprek met een gast. Van cypherpunkpioneers tot grootbanken die aan de haal gaan met stablecoins, van Bitcoin tot Ethereum tot CBDC's. Alles passeert de revue. Reageren? Stuur dan een mail naar cryptocast@bnr.nl Gasten Bart Mol is oprichter en host van Satoshi Radio, en Het Crypto Journaal. Daarnaast is Bart analist bij kennisplatform Bitcoin Alpha. Veronique Estié is econoom, belegger, schrijver en oprichter van YoungTrader. Met haar platform wil ze financiële kennis toegankelijk maken. Host Daniel Mol is redacteur en presentator van de Cryptocast. Hij is sinds 2017 met Bitcoin bezig en kwam in 2021 bij het team van de Cryptocast. Redactie Daniel Mol Matthijs Damsteeg See omnystudio.com/listener for privacy information.

The debate over immigration reform and ag labor has some big holes on both sides of the argument.

In dieser Episode nehme ich Dich mit zum FIT - Forum für Innovation und Transformation. Eine Konferenz der Kreissparkasse Miesbach Tegernsee. Hier findest Du weitere Infos: [FIT](https://www.fitforum.org/) In meiner Keynote "Wie Wandel gelingt!" spreche ich darüber, warum Transformation nur gelingt, wenn du und deine Mitarbeitenden wirklich emotional an die Zukunft eures Unternehmens glauben. Ich zeige dir, weshalb Wandel weit über Prozessoptimierung hinausgeht und wie du als Führungskraft Orientierung geben kannst – selbst dann, wenn der Weg unklar ist. Außerdem erfährst du, weshalb radikale Kundennutzen-Fokussierung Agilität freisetzt und wie Plattformen wie das FIT Forum regionale Innovationskraft stärken. Kernthemen: - Warum emotionale Bindung der Schlüssel zu echter Transformation ist - Wie du durch radikale Kundennutzen-Fokussierung Klarheit und Agilität erzeugst - Warum Ungewissheit normal ist – und wie du sie für dich nutzen kannst - Welche Rolle du als „Bergführer“ im Wandel einnimmst - Wie das FIT Forum als Innovationsplattform Menschen verbindet und Veränderung beschleunigt Wenn Dir diese Folge gefallen hat, dann freue ich mich über Deine Bewertung mit 5 Sternen bei Apple Podcasts und wenn Du meinen Podcast weiterempfiehlst. Mail mir gerne Deine Gedanken zur Folge unter jw@juergenweimann.com. Lass uns verbinden: [LinkedIN](https://www.linkedin.com/in/juergenweimann/) Liebe Grüße, Jürgen [Abonnier hier meinen Newsletter](https://juergenweimann.com/juergen-weimann-newsletter/)

Sarah Poland, MD, lead author of a recently published article in the journal ONCOLOGY titled Advances in Immunotherapy for Breast Cancer, highlighted key findings from her review in a conversation with CancerNetwork®.1 Throughout the discussion, she spoke about: Shifting Perspectives on Immunogenicity: Historically, breast cancer was considered a “cold,” poorly immunogenic tumor due to low tumor mutational burden (TMB) and few tumor-infiltrating lymphocytes (TILs). Poland highlighted how clinical research has shifted this perspective, particularly through the study of triple-negative breast cancer (TNBC), which often exhibits higher PD-L1 expression and immune infiltration.Key Clinical Milestones: The review highlighted foundational data that established immunotherapy as a standard of care: Early-Stage TNBC: The phase 3 KEYNOTE-522 trial (NCT03036488) established pembrolizumab (Keytruda) plus chemotherapy as a standard neoadjuvant treatment for stage II to III TNBC.2 Metastatic TNBC: The phase 3 KEYNOTE-355 trial (NCT02819518) demonstrated the benefit of pembrolizumab in PD-L1–positive metastatic disease.3 Managing Toxicity and Rechallenge: Poland addressed the feasibility of pembrolizumab rechallenge after an immune-related adverse effect (irAE), emphasizing that while possible, it requires a highly individualized approach based on the severity and timing of the initial toxicity.The Future Landscape: Beyond PD-1/PD-L1 inhibitors, the discussion covered emerging technologies that are poised to redefine treatment: Antibody-Drug Conjugates (ADCs): Exploration of novel combinations of ADCs with immunotherapy. Emerging Modalities: The potential role of bispecific antibodies and vaccine trials utilizing tumor antigens. Subtype Expansion: Emerging evidence supporting the efficacy of immunotherapy in hormone receptor–positive and HER2-positive subtypes, moving beyond the traditional focus on TNBC. Unmet Educational Needs: Poland emphasized the importance of resources that connect providers and patients, particularly in translating complex trial data into clinical practice and addressing patient concerns regarding the newest therapies and trials.Poland is from the Department of Medicine in the Section of Hematology/Oncology at The University of Chicago.References1.        Poland S, de Oliveira Andrade M, Nanda R. Advances in immunotherapy for breast cancer. Oncology (Williston Park). 2026;40(1):8-15. doi:10.46883/2026.259210612.        Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810-821. doi:10.1056/NEJMoa19105493.        Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217-226. doi:10.1056/NEJMoa2202809

BACK in 2004. I took our kids back to Africa in 2004. Here's what happened. Due to a minor plane crash and having to make the trip overland, our kids went on into the Congo and I stayed behind with no plans for the week in the Central African Republic. THEN the invitations poured in! I happily taught many groups, pastors, deaconesses, school teachers, night watchmen and even high government officials! They were trilled at the positive news of Eden!NOW in 2026! We have two special events coming up! YOU are invited to our Event at the HQ of the American Bible Society on March 21 2026! We'll be presenting the Tru316 Medallion Award to ABS President Dr. Jennifer Holloran and our Keynote speaker will be Dr. Beverly Nyberg! Dr. Nyberg studied at the University of Nebraska and Trinity Evangelical Divinity School. she has been Adjunct Professor at The George Washington University and Senior Consultant at Common Root Consulting. At the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) State Dept. she for 11 years she was responsible for the US Government global programs for children affect by HIV/AIDS. PEPFAR. She also had served with the Peace Corps in Africa and provided field leadership in DR Congo with The Evangelical Free Church Mission. The Tru316 Foundation (www.Tru316.com) is the home of The Eden Podcast with Bruce C. E. Fleming where we “true” the verse of Genesis 3:16. The Tru316 Message is that “God didn't curse Eve (or Adam) or limit woman in any way.” Once Genesis 3:16 is made clear the other passages on women and men become clear too. You are encouraged to access the episodes of Seasons 1-11 of The Eden Podcast for teaching on the seven key passages on women and men. Are you a reader? We invite you to get from Amazon the four books by Bruce C. E. Fleming in The Eden Book Series (Tru316.com/trubooks). Would you like to support the work of the Tru316 Foundation? You can become a Tru Partner here: www.Tru316.com/partner

Ep 278 Pages, Keynote, and Numbers 15 Go Freemium Kuzu database company joins Apple's list of recent acquisitions iOS 26.3 Features: Everything New in iOS 26.3 Tauri 2.0 — The cross-platform app building toolkit Rork — Create mobile app in minutes, using AI OpenClaw, OpenAI and the future | Peter Steinberger jordy: I wasted 80 hours and $800 setting up OpenClaw - so you don't have to. I used Xcode 26.3 to build an iOS app with my voice in just two days - and it was exhilarating Steve Troughton-Smith: In case you missed it, I've been testing the limits of Xcode 26.3's agentic programming support this week, using Codex. This entire app used 7% of my weekly Codex usage limit. Compare that to a single (awful) slideshow in Keynote using 47% of my monthly Apple Creator Studio usage limit. Aditya: Cons of being a software engineer no one really talks about… HackerTyper: Use This Site To Prank Your Friends With Your Coding Skills :) Virtualization Explained: We Install 1TB of RAM for HyperVisors, Virtual Machines, and Docker! Mr. Macintosh: The very first email from space was sent on a Macintosh Portable by James Adamson & Shannon Lucid aboard the Shuttle Atlantis STS-43 Public Domain Remastered — Looney Tunes MEGA Compilation, 118 FULL Episodes in 4K 60FPS Zahvalnice Snimano 20.2.2026. Uvodna muzika by Vladimir Tošić, stari sajt je ovde. Logotip by Aleksandra Ilić. Artwork epizode by Saša Montiljo, njegov kutak na Devianartu

Guest Co-host: Steve Tupper. F-35 Glitch... Swift Fuel UL 100R... Headbutt... A320 Type. All this and more on Uncontrolled Airspace Podcast. Recorded Sep 25, 2025. () [#772] {37:30} [UCAP1113B]

What if growth in 2026 isn't about doing more — but choosing better? In this keynote from Benjamin Mena's Elite Recruiter Sales & BD Summit, Kortney Harmon reframes what winning looks like in today's staffing market.In this episode, you'll hear insights from Kortney Harmon's keynote at Ben Mena's Sales and BD Summit, where she explores why narrowing focus, redesigning revenue strategy, and protecting the right relationships are critical in today's staffing market. As sales cycles lengthen and effort becomes more expensive, Kortney breaks down how intentional account selection, system alignment, and leadership judgment can eliminate wasted activity and margin erosion. From confronting burnout and revenue concentration to building repeatable processes that reduce reliance on heroics, she shares practical frameworks to help firms move from reactive selling to relationship-driven growthWhether you're an agency leader, full-desk producer, or building the next phase of your firm's growth, this episode challenges you to rethink where your effort is going — and whether it's truly compounding.____________Follow Benjamin Mena LinkedIn: LinkedIn: BenjaminBenjamin Mena with Select Source Solutions: hereThe Elite Recruiter Podcast Instagram: https://www.instagram.com/theeliterecruiter/Follow Crelate on LinkedIn: CrelateWant to learn more about Crelate? Book a demo hereSubscribe to our newsletter: The Full Desk Experience

Was haben eine Kinderklinik, ein Tattoo am Hals und eine Stuntfrau gemeinsam? Eine Frau namens Jasmin Dreuw – und eine Geschichte, die dich nicht nur fesseln, sondern tief in deinem Herzen treffen wird. In dieser mitreißenden Keynote – entstanden im Killer Keynote Bootcamp mit Tobias Beck – nimmt dich Jasmin mit auf ihre persönliche Achterbahnfahrt des Lebens. Von einem kleinen Mädchen mit einem seltenen Genfehler, das mehr Zeit im Krankenhaus als auf dem Spielplatz verbrachte, hin zu einer Frau, die ihren Körper aus Flugzeugen stürzt und in brennende Autos klettert – als erfolgreiche Stuntfrau.

Today, on Notable Leaders' Radio, I speak with  Melissa Muir, acclaimed jewelry artist and teacher. She highlights how embracing life's unexpected pivot points opens new paths for creativity, personal growth, and transformation. In today's episode, we discuss: Honor your pivot points. Notice the moments whernt feels like a dead end. What would be different if you chose to see it as a time to redesign? Use every closed door or "mistake" as information for your next step. Allow creativity to be learned. Release the belief that you're "not creative" and give yourself permission to practice, experiment, and grow your skills one imperfect attempt at a time. Come home to your own truth. Gently question inherited beliefs, rules, and expectations so you can build a true relationship with yourself, the divine, and others that feels loving, spacious, and genuinely your. Choose communities that help you flourish. Intentionally seek out people who are curious, creative, and kind, knowing that "creativity breeds creativity" and you don't have to do it alone. Talk gently to your younger self. Revisit the bullied, lonely, or hurting version of you and let them know what's coming, so you can release old pain and stand more fully in who you are now. RESOURCES: Guest Bio: Melissa Muir is a metalsmith, educator, and trusted voice in the jewelry industry, known for bridging traditional craftsmanship with modern tools and techniques. With decades of hands-on experience at the bench, she specializes in jewelry fabrication, welding, stone setting, and emerging technologies such as pulse arc welding and engraving. As an educator and public speaker, Melissa is passionate about making complex processes approachable for both professional jewelers and dedicated hobbyists. Through workshops, online courses, product testing, and in-depth tool reviews, she empowers makers to work more confidently, efficiently, and creatively. Her clear, honest teaching style has made her a go-to resource for jewelers seeking practical knowledge they can immediately apply. Melissa is also the founder of Melissa Muir Metalsmith, where she shares education, demonstrations, and industry insights through video content, webinars, and live events. Her work focuses on raising the standard of jewelry education worldwide while inspiring makers to embrace innovation without losing sight of craftsmanship. Whether at the bench, on stage, or behind the camera, Melissa Muir is dedicated to helping jewelers refine their skills, invest wisely in tools, and rediscover joy in the making process. Website/Social Links: Melissa@melissamuir.com Www.instagram.com/metalsmithmelissa   Www.youtube.com/melissamuir Www.tictok.com/metalsmithmelissa Belinda's Bio:  Belinda is a sought-after Leadership Advisor, Coach, Consultant and Keynote speaker and a leading authority in guiding global executives, professionals and small business owners to become today's highly respected leaders. As the Founder of BelindaPruyne.com, Belinda works with such organizations as IBM, Booz Allen Hamilton, BBDO, The BAM Connection, Hilton, Leidos, Yale School of Medicine, Landis, and the Discovery Channel. Most recently, she redesigned two global internal advertising agencies for Cella, a leader in creative staffing and consulting. She is a founding C-suite and executive management coach for Chief, the fastest-growing executive women's network. Since 2020, Belinda has delivered more than 72 interviews with top-level executives and business leaders who share their inner journey to success; letting you know the truth of what it took to achieve their success in her Notable Leaders Radio podcast. She gained a wealth of expertise in the client services industry as Executive Vice President, Global Director of Creative Management at Grey Advertising, managing 500 people around the globe. With over 20+ years of leadership development experience, she brings industry-wide recognition to the executives and companies she works with. Whether a startup, turnaround, acquisition, or global corporation, executives and companies continue to turn to Pruyne for strategic and impactful solutions in a rapidly shifting economy and marketplace.   Website: Belindapruyne.com Email Address: hello@belindapruyne.com LinkedIn: https://www.linkedin.com/in/belindapruyne  Facebook: https://www.facebook.com/NotableLeadersNetwork.BelindaPruyne/  Twitter: https://twitter.com/belindapruyne?lang=en  Instagram: https://www.instagram.com/belindapruyne/ 

Every year the Chamber sponsors a poll of San Franciscans regarding the health and vitality of our economy and well being of the City by the Bay. The results were unveiled last week at the City Beat breakfast. Mayor Lurie gave the Keynote address and CEO Rodney Fong presided. In today's podcast, Rodney discusses the poll results.

In our February episode, we marked American Heart Month with Dr. Michael Ghalchi, the founder and medical director of Manhattan Cardiovascular Associates and a Clinical Instructor in the Department of Medicine at NYU Grossman School of Medicine. Dr. Ghalchi explained the importance of regular screenings and shared lifestyle habits that can keep your heart strong. In this month's Key Note, Dr. Ghalchi reviews the key health numbers to aim for to help you stay on track and live your best life.  The Takeaway We want to hear from you! Please complete our survey: 1199SEIUBenefits.org/member-feedback. Drop us a line at our social media channels: Facebook // Instagram // YouTube. Find out where you stand heart-wise by making an appointment with your primary care physician. Don't have one? Find one at our Provider Directory: www.1199SEIUBenefits.org/find-a-provider.  Visit the Healthy Living Resource Center for wellness tips, information and resources; www.1199SEIUBenefits.org/healthyliving. Get to know your numbers at www.1199SEIUBenefits.org/healthyhearts. Need support managing chronic conditions such as type 2 diabetes, hypertension or overweight? Learn about our partnerships: visit www.1199SEIUBenefits.org/the-choice-is-yours/ Browse healthy recipes and meal-prep tips at www.1199SEIUBenefits.org/food-as-medicine. Get inspired by fellow members through our Members' Voices series: www.1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to join webinars on building healthy meals, managing stress and more: www.1199SEIUBenefits.org/videos. Visit our  YouTube channel to view a wide collection of healthy living videos: www.youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: www.1199SEIUBenefits.org/wellnessevents. Guest Bio Michael Ghalchi, MD, FACC is a board-certified cardiologist and the founder and medical director of Manhattan Cardiovascular Associates, a New York City–based cardiology practice dedicated to making high-quality cardiovascular diagnostics and care accessible, efficient and patient-centered. He is also a Clinical Instructor in the Department of Medicine at NYU Grossman School of Medicine. He graduated summa cum laude from the University of Pennsylvania and earned his medical degree from the New York University School of Medicine.   At Manhattan Cardiovascular Associates, Dr. Ghalchi focuses on delivering timely, evidence-based cardiovascular care supported by advanced in-office diagnostics, streamlined access and a concierge-level patient experience. His clinical work emphasizes early detection, accurate diagnosis and thoughtful management of cardiovascular disease across a broad patient population. Dr. Ghalchi is also the founder and Medical Director of Apollo 360 Health, a digital preventive-care platform designed to extend high-quality cardiovascular and lifestyle medicine beyond the clinic walls. Apollo 360 Health integrates remote monitoring, data-driven insights and multidisciplinary coaching to help patients proactively manage risk factors, improve outcomes and sustain long-term health. Across both organizations, Dr. Ghalchi's mission is to modernize cardiovascular care by combining rigorous clinical standards with innovative delivery models — ensuring patients receive the right care, at the right time, in the setting that best supports lasting health.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Shelby Williams.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Shelby Williams.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Shelby Williams.

I dig into the Kentucky Auditor's report that found over $133 million in questionable spending by the Beshear administration. The report found issues with:

Rejoignez la communauté iWeek et soutenez-nous sur patreon.com/iweek !Voici l'épisode 266 d'iWeek (la semaine Apple).Événement Apple, le 4 mars : MacBook, MacBook Pro M5 Pro / Max et iPhone 17e ?Enregistré en streaming, lundi 16 février 2026 à 18h30, enregistrement accessible en direct pour nos soutiens Patreon. Désormais, eux seuls peuvent suivre le streaming de chaque épisode grâce à un lien que nous leur envoyons chaque semaine. Faites comme eux et profitez du chat, intervenez en visio en cliquant sur le bouton sous le lecteur vidéo. Quant au replay vidéo, sans le bonus, il continue d'être disponible pour tous sur YouTube.Présentation : Benjamin Vincent, journaliste, producteur et présentateur de Les Voix de la Tech, avec la participation d'Elie Abitbol, ex-président des Apple Premium Resellers en France.Au sommaire de cet épisode 266 : la nouvelle est tombée juste avant le démarrage de l'enregistrement : Apple tiendra une “expérience spécial Apple“, mercredi 4 mars prochain, à New York (9h du matin), Londres (14h) et Shanghai. Il ne s'agit ni d'une keynote, ni d'un Special Agent. Alors qu'est-ce qu'Apple pourrait y annoncer ? Et pourquoi ce format particulier sur trois continents simultanément ? On pense évidemment au Mac portable low cost à processeur d'iPhone, aux nouveaux MacBook Pro M5 Pro et Max, et peut-être Ultra aussi. On pense également à l'iPhone 17e et à la domotique, pourquoi pas...Dès le début de l'épisode, nous revenons sur le retard d'Apple autour de l'IA puisque Siri ne devrait pas arriver avec iOS 26.4 mais au mieux la 26.5 ou - pire - iOS 27... à l'occasion de sa présence au WAIFC à Cannes, Benjamin vous propose une interview de Marco Landi, ex-VP d'Apple en charge du marketing mondial. Il raconte son étonnement face aux errements de Tim Cook et à une stratégie incompréhensible selon lui.L'info de la semaine concerne iOS 27 justement mais aussi les prochains iPhone 18 Pro et Pro Maxdont Mark Gurman nous dit déjà qu'il ne faut pas trop en attendre...Enfin, le bonus exclusif qui vous est réservé, chers soutiens, est de retour : aujourd'hui, des nouvelles de CarPlay dans les Tesla !Rendez-vous mardi 24 févier 2026 à partir de 18h30 en direct pour l'épisode 267 !Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Karnevalskater trifft Open-Source-Kater: Zwischen FOSDEM-Raumsuche, MySQL-Gerüchten und ethischen Grundsatzdebatten stolpern wir durch Tech-Trends und AI-News. Dazu gibt's Abo-Detox, Desktop-Frust und die Erkenntnis: Digitale Souveränität beginnt manchmal mit „Kündigen“-Button statt Keynote. Blast from the Past MySQL - Bericht vom FOSDEM Stand Rant extended - same as posting blogposts on linkedin applies - of course - to medium. Static Site Generators with AsciiDoc support Toter der Woche Google Pixel 3a Untoter der Woche notepads Windows Notepad Ursache Markdown feature Microsoft seite Notepad++ AI der Woche AI agent seemingly tries to shame open source developer for rejected pull request AI found 12 of 12 OpenSSL zero-days (while curl cancelled its bug bounty) Selfish AI Anthropic raises $30B Series G funding at $380B post-money valuation (Anthropic) Nvidia shares are down after a report that its OpenAI investment stalled. Here's what's happening News Wero: Commerzbank macht mit

“I hope you continue to be extremely intentional in choosing to be exactly where your feet are every moment that you are.”Lynn WongEpisode Summary:In this keynote episode from Zweig Group's ElevateAEC2025 Conference, Lynn Wong delivers a powerful talk on what it takes to thrive—both personally and collectively—in the architecture, engineering, and construction world. Drawing from her global leadership experience and some transformative moments along the way, Lynn explores where well-being, conscious leadership, and innovation meet.She opens up about her own story: climbing the ladder across three continents, hitting burnout hard, then finding her way back through slowing down and living with intention. Lynn connects the dots between wellness science and team dynamics, the importance of unlearning old patterns, and how to navigate the disruptions reshaping the AEC industry. Her message is clear: make conscious choices, take care of yourself, and build resilience—in your own life and across the profession.Key Takeaways:Intentional Leadership: Being fully present, knowing oneself deeply, and making conscious choices are foundational to thriving as a leader—especially amid rapid industry change.Slowing Down to Speed Up: Sustainable progress in AEC comes not from relentless pace but from mindful “slowing down”—pausing for clarity, reflection, and purposeful action.Personal Well-Being Fuels Teams: Core habits like breathing deeply, moving joyfully, mindful eating, and sleeping gratefully are essential for personal health, which in turn impacts collective performance and creativity.Embrace Unlearning for Innovation: Growth and transformation in organizations and individuals require an openness to “unlearning” old habits and perspectives and a willingness to navigate discomfort.Celebrate Team Strengths: Success in the AEC industry is rooted in collaboration, recognizing individual and team strengths, and honoring human potential in every project.All this and more on this episode of the Zweig Letter podcast.Links referenced in this episode:Connect with Lynn Wong on LinkedInLearn about the Zweig Letter and subscribe: https://thezweigletter.com/Connect with Randy Wilburn on LinkedInGet your FREE Subscription to the Zweig Letter Newsletter.Stay tuned for more

Bright pink suits, big bills, giant golf clubs, and facebook ads targeted at people who like moustaches? Yep, that's exactly what Rich is going to talk about on the Throwback Thursday episode. It's from a keynote he gave recently at the Service Nation Alliance on the topic of guerrilla marketing. What Rich is talking about is using your brains and your ingenuity to generate interest and leads instead of just your checkbook. This is one of the most fun and interesting keynotes Rich gives--and has loads of great ideas that you might want to implement, regardless of how big your company is.

Enjoy this full replay of Karly Iacono's keynote presentation from the 2026 Princeton Real Estate Market Forecast event.In this session, Karly breaks down why 2026 is shaping up to be a year of clarity as the real estate market thaws and expectations reset. She highlights the economic backdrop, the state of the capital markets, and the most important trends across office, retail, industrial, and multifamily assets.You'll hear what's beginning to stabilize, where pricing is shifting, and why disciplined underwriting is more critical than ever. Karly also explores how emerging technologies, including artificial intelligence, are starting to transform commercial real estate workflows and reshape risk management.Key Timestamps: • 00:07 Introduction • 01:49 Economic impacts to CRE • 06:26 Capital markets • 08:06 Buyer mix • 10:32 Lending profile • 13:43 Cap rates • 14:33 Office • 18:17 Retail • 23:02 Industrial • 26:16 Multifamily • 29:03 Future of CRE: technology and tools shaping workflow + risk analysis • 40:22 2026 summary • 41:02 Where to learn more + connectRead CBRE's U.S. Real Estate Market Outlook for 2026: https://www.cbre.com/insights/books/us-real-estate-market-outlook-2026#commercialrealestate #realestate #marketoutlook #economicoutlook #capitalmarkets #realestateinvesting #marketforecast #cre Warning-IRS Circular 230 Disclosure: CBRE and its affiliates do not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein is not intended or written to be used, and cannot be used, by the recipient of any Information for the purpose of avoiding U.S. tax-related penalties; and was written to support the promotion or marketing of the transaction or other matters addressed herein. Accordingly, any recipient of this video should seek advice based on your particular circumstances from an independent tax advisor. You also agree that the information herein down not constitute legal or other professional advice and you should obtain legal advice from a qualified attorney licensed in your state. The opinions contained in this video are those of Karly Iacono and may not represent those of CBRE. All content is for educational purposes only. The following content may contain the trade names or trademarks of various third parties, and if so, any such use is solely for illustrative purposes only. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with, endorsement by, or association of any kind between them and CBRE or Karly Iacono.

Today, on Notable Leaders' Radio, I speak with you as I launch the new "Still Becoming" series. I highlight how the journey of growth and self-discovery continues long after success is achieved, inviting you to explore the moments of untapped courage, unexpected opportunities, and personal evolution that unfold beyond traditional milestones. In today's episode, we discuss: Explore life beyond achievement. Reflect on the moment when hitting goals and earning recognition stopped answering everything, and consider whether it's time to redesign what success looks like for you now. Listen for your quiet evolution. Notice the subtle inner shifts, new perspectives, expanded freedom, unexpected gentleness with yourself, that change how you see your work, your impact, and what's truly possible. Let the unexpected become a doorway. Revisit the chapters you never planned, a random elevator conversation, a surprise opportunity, a path you "stumbled into", that you now wouldn't give back for anything. Tap your untapped courage. Acknowledge the deeper reservoir of bravery it takes to step away from predictability, trust your inner knowing, and say yes when your path is no longer obvious or linear. Choose meaning over momentum. Ask where you're sprinting on autopilot and where you're ready to consciously trade speed for impact, alignment, and the kind of contribution that actually matters to you. Define what "more" means for you now. Let go of one-size-fits-all ambitions and get curious about your current version of "more" in this season—more joy, more presence, more service, more creativity—and honor that as valid and enough. RESOURCES: Belinda's Bio: Belinda is a sought-after Leadership Advisor, Coach, Consultant and Keynote speaker and a leading authority in guiding global executives, professionals and small business owners to become today's highly respected leaders. As the Founder of BelindaPruyne.com, Belinda works with such organizations as IBM, Booz Allen Hamilton, BBDO, The BAM Connection, Hilton, Leidos, Yale School of Medicine, Landis, and the Discovery Channel. Most recently, she redesigned two global internal advertising agencies for Cella, a leader in creative staffing and consulting. She is a founding C-suite and executive management coach for Chief, the fastest-growing executive women's network. Since 2020, Belinda has delivered more than 72 interviews with top-level executives and business leaders who share their inner journey to success; letting you know the truth of what it took to achieve their success in her Notable Leaders Radio podcast. She gained a wealth of expertise in the client services industry as Executive Vice President, Global Director of Creative Management at Grey Advertising, managing 500 people around the globe. With over 20+ years of leadership development experience, she brings industry-wide recognition to the executives and companies she works with. Whether a startup, turnaround, acquisition, or global corporation, executives and companies continue to turn to Pruyne for strategic and impactful solutions in a rapidly shifting economy and marketplace. Website: Belindapruyne.com Email Address: hello@belindapruyne.com LinkedIn: https://www.linkedin.com/in/belindapruyne  Facebook: https://www.facebook.com/NotableLeadersNetwork.BelindaPruyne/  Twitter: https://twitter.com/belindapruyne?lang=en  Instagram: https://www.instagram.com/belindapruyne/ 

I am happy to welcome you to the inaugural podcast keynote! This is the official episode 400, so if you're listening to this in February there are 399 episodes to scroll beneath this one. I wanted to mark the 400th episode with something--- in episode 200 we had a town hall and it went really well. I am not sure where this will go on Laura's CV, but I am really happy she accepted the invitation to make something new and to be creative with me on this podcast! Dr. Laura Alfrey –is an associate professor at Monash University in Australia her research interests are in HPE and the ways which policy, professional learning and practice contribute to inclusive and educative experiences for everyone. Today she will share her innovative research in fitness testing…. But beyond publishing copious articles, getting cited hundreds of times a year for her work- Laura also serves the field by being on the Editorial Board for Curriculum Studies in HPE, Sport Education and Society, and the Journal of Teaching in Physical Education…AND MANY MORE!This podcast keynote is about fitness testing in PE, from an Australian lens, with a few notes about the American context, and some commentary by US based researchers as well. Here is a link to the video Laura showed: https://www.youtube.com/watch?v=VcH_IErqIXMThis is the article Chuck noted in his comment: Charles B. “Chuck” Corbin (2026)National Youth Fitness Tests and Awards: Dispelling Misconceptions andMisinformation, Journal of Physical Education, Recreation & Dance, 97:1,3-5, DOI: 10.1080/07303084.2025.2579444 To link to this article:https://doi.org/10.1080/07303084.2025.2579444

This episode we share a keynote address that Dallas gave at a R3 conference.

In der Außensicht sind wir ein Land mit lange verleugneter Nazi-Vergangenheit, das seine Verantwortung in Europa gerne hinter der Neutralität versteckt. Eine überholte Denkweise in der neuen Weltpolitik, argumentiert Ursula Plassnik. Beim Symposium der Salzburger Festspiele 2025 hielt die ehemalige ÖVP-Außenministerin eine ungewöhnliche Keynote. Hosted on Acast. See acast.com/privacy for more information.

Two cataclysmic events have shaped Dr Lucy Hone’s relationship with grief, and resilience.

SummaryThe keynote explores the relationship between energy and human flourishing, emphasizing the evolution of production methods from the Industrial Revolution to modern Bitcoin mining. It highlights the importance of storytelling in conveying complex ideas and showcases various innovative projects that exemplify the potential of decentralized energy solutions. The discussion culminates in a call to recognize the collective efforts of individuals in achieving continuous production and fostering human flourishing.Takeaways- Energy is essential for human flourishing.- The Industrial Revolution set the stage for modern production.- Henry Ford's vision of continuous production is still relevant today.- Modern technology allows for decentralized production.- Bitcoin mining can be a steward of energy resources.- Stories are crucial for understanding complex concepts.- Innovative projects are transforming energy consumption.- Decentralization empowers individuals in the energy sector.- Continuous production can lead to human flourishing.- Collective efforts are key to achieving sustainable energy solutions.Chapters00:00 Setting the Stage for Energy and Human Flourishing04:55 The Evolution of Production: From Ford to Bitcoin09:55 Stories of Innovation: Real-World Applications of Bitcoin Mining12:48 Decentralization and the Future of EnergyKeywordsenergy, human flourishing, Bitcoin, production, innovation, decentralization, mining, stories, industrial revolution, continuous production

View this video at https://macmost.com/how-to-keep-using-pages-numbers-and-keynote-if-you-dont-want-apple-creator-studio.html. If you only use Pages, Numbers and Keynote and don't want the Apple Creator Studio subscription, you should get the new apps, and just ignore the subscription features. Here's how to hide some of them away.

Featuring an interview with Dr Terence Friedlander, including the following topics: Final analysis of the Phase III, open-label, randomized POTOMAC trial (0:00) KEYNOTE-905 trial: Perioperative enfortumab vedotin with pembrolizumab for muscle-invasive bladder cancer (MIBC) (5:25) The neoadjuvant gemcitabine intravesical system TAR-200 for patients with MIBC: Primary analysis of the SunRISe-4 trial (14:07) Circulating tumor DNA-guided therapies for MIBC (18:41) CME information and select publications

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducing costs and toxicity with lower doses of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center, Los Angeles. My guest today, I think, is going to be a really riveting one. It's Dr. Atul Batra, who is an additional professor of medical oncology at the All India Institute of Medical Sciences, or AIIMS, in New Delhi. And he's also the senior author of the PLANeT study. It's a very compelling study that evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer. And it's really a big part of a growing body of research that's showing balanced efficacy when we use lower doses of immunotherapy instead of standard doses to reduce cost, as well as potentially toxicity. I think this has huge implications for our global audience, and I'm so thrilled to have you on the podcast today, Dr. Atul Batra, welcome. Dr. Atul Batra: Thank you, Dr. Pal. Dr. Monty Pal: And we'll just take it with first names from here since we're both friends. I have to give the audience some context. Atul, I had the great honor of visiting AIIMS New Delhi. For those that don't know, this is really, you know, the Harvard Medical School of India. It's the most competitive institution for medical training. And on the back end of that, there's also incredible resources when it comes to clinical trials and infrastructure. I just wanted to have you give the audience sort of a scope of the types of trials that you've been able to do at AIIMS New Delhi. Dr. Atul Batra: Thank you, Monty. So, I work at the All India Institute of Medical Sciences, and we had the honor and pleasure of having Monty here this month. And people are still in awe of his lectures that he delivered there. Coming back to our institute, so it's kind of a medical college. It's one of the oldest ones, it was built in 1956. We are lucky enough that we get the best of the residents and fellows because they have to go through an exam, a competitive exam, and mostly it's them who come to us and we're able to do some good work out here. Regarding the trials that we have conducted, we do conduct some investigator-initiated studies, and we try to answer the questions where we can help our own patients. Like, for example, this PLANeT study. Every other patient in the clinic was almost not able to afford Keytruda at the full dose, pembrolizumab, and we had a lot of evidence creeping in that a lower dose might be helpful. And that's how we planned this study. Before that, there are certain cancers that are peculiar to India, like gallbladder cancer, head and neck cancers. These are much more common in India as compared to the U.S., and there are some good studies that have been conducted from our own institute by our senior colleagues which have been presented at ASCO and published in the JCO. We also did the capecitabine hand-foot syndrome study that was known as the D-ToRCH study: 1% diclofenac gel that became the standard of care to prevent hand-foot syndrome.  So, that's kind of a brief overview of investigator-initiated studies. India is slowly and steadily becoming a partner of the global registration trials. And it's more recently, the last five years or so, we have seen that the number of phase 2 and phase 3 trials are increasing and we are able to offer now these trials as well to our patients. Dr. Monty Pal: That was a terrific overview. I just want to highlight for the audience, as we go through some of your discussions today around specific trials, the speed at which this can be done. Just for context, for me to accrue a clinical trial of 30 patients – I think many people have probably come across some of the work that I've done in the microbiome space – at a single institution, 30 patients, right, takes me about a year and a half, two years. We're going to go through some trials today where Dr. Batra and his team have actually, in fact, accrued close to 200 patients over a span of just a year, which is just remarkable by, I would say, any American standard. So, I see a real need for partnership and Atul, I'll kind of get back to that at the end. But without further ado, the focus of this podcast today, I think, is really this terrific presentation you gave in an oral session at ESMO and subsequently published in Annals of Oncology related to the PLANeT study. Would you give the listeners some context around what the study entailed and population and so forth? Dr. Atul Batra: So, we know the KEYNOTE-522 became the standard of care for triple-negative breast cancer, where Keytruda, when added at 200 mg, the standard dose every three weeks with neoadjuvant, increases the pCR from around 51% to 64% by a magnitude of around 13%. However, in India and other low-middle income countries, less than 5% of the patients actually have access to this dose of pembrolizumab. So, our standard of care was actually just chemotherapy till now. And this kind of led us to design this trial. There are data that come from previous trials conducted in India, from the Tata Memorial, done in head and neck space, some other studies done in Hodgkin's lymphoma, that a much lower dose, probably around one-tenth of the dose, works well in these cancers. So, that's where we designed the PLANeT study, where we gave the standard neoadjuvant chemotherapy in the control arm, and in the experimental arm we added 50 mg of pembrolizumab. This was given every six weeks for three doses. So, that's a total of 150 mg over the neoadjuvant period as compared to 1,600 mg that was given in the KEYNOTE-522 study. So, this was almost one-tenth of the study. Dr. Monty Pal: So, a tenth of the dose, which is just remarkable. I mean, that's just such an interesting concept. Dr. Atul Batra: And the results, when we – the primary outcome, this was a phase 2 study. We just wanted to see, is there a signal of activity? And to even our surprise, when we looked at the pathological complete response rates, in the control arm this was 40.5%, and in the experimental arm this was 53.8%. So, a difference came to around 13.3%; it was numerically, I mean, so much similar to what KEYNOTE-522 had with just these many doses. So, this was around 160 patients randomized over one year. We could randomize them in one year because of the load that we see. And the primary endpoint was met, and we could see that the path complete response did show a remarkable increase. We are still following these patients to see whether there is a difference in event-free survival at a longer follow-up. Until now, it's a small follow-up, so the number of events absolute, are different: four events in the experimental arm and 11 events in the control arm. So, we are seeing some signal even in this much short follow-up period as well. But we need to see more of what happens in the longer term. Dr. Monty Pal: That's so impressive. I wonder, with this lower dose, do you attenuate toxicity at all as far as you can gather? Dr. Atul Batra: So, although we shouldn't be doing kind of cross-trial comparisons, but if you look at thyroid dysfunction, we saw that around 10% of our patients had this thyroid dysfunction. This was compared to 15% in the KEYNOTE-522, that was a larger sample size though. But we're seeing that all the toxicities are somewhat less as compared to those in the standard dose. So, the exposure is less, but I mean, I can't really commit definitely on this. For this we would need much more data to say this with more confidence. Dr. Monty Pal: Yeah. I'm going to ask you a really tough question to follow up, and this is probably something that's on everyone's mind after reading a study like this. Is this something that is disease-specific that needs to be replicated across other histologies? The reason I ask this is, you know, you think about paradigms like, for instance, in the States we're toying between intravenous versus subcutaneous delivery of checkpoint inhibitors, and we have studies focused in specific histologies that might justify use across all histologies. With this particular phenomenon, do you think we need to do dedicated studies in renal cell or in colon cancer and other places where, you know, in selected settings we might use checkpoint inhibitors and then decide whether or not there's this dose equivalence, if you will? Dr. Atul Batra: That's a real tough one, though. But I'm happy to share that there are several ongoing studies within India currently. At our institute, my colleagues are leading studies in lung cancer space, cervical cancer. There was already a publication from Tata Memorial Hospital in head and neck cancers and we see that the signal has been consistent throughout. Regarding renal cancer, there was one study that was presented for sure at ASCO from CMC Vellore, that's again a center in South India. That was in RCC at a much lower dose. And for patients who cannot take the full dose, we actually are offering lower dose nivolumab in such patients and we are seeing responses. I mean, we haven't done those randomized trials again because the numbers are much lower in kidney cancers, we know. We could do this trial in triple-negative ones because we had support and we had numbers to conduct this trial. But I'm sure this should be a class effect. I mean, when we can get tumor-agnostic approvals, then some real-world data has come up in almost all tumors, we have seen that consistent effect across tumors. And as we speak of today, I'm also delighted to share that in India, yesterday, we had the first biosimilar of nivolumab and that's now available at a much, much lower price than the original patent product. There was a long ongoing lawsuit that was there, that's over now, and from yesterday onwards, I'm so happy to share here that we would have the first biosimilar of nivolumab that's available. That's going to bring the cost to almost like one-tenth already. Dr. Monty Pal: Wow. That's huge.  I'm going to be very selfish here for a second and focus on a study that is in the renal cell space that your group has done. You know, when it came out, I was really sort of intrigued by this study as well and it reflects sort of a different capability, I think, of AIIMS New Delhi, and that's in the, what I'm going to call, biomarker space. This, for the audience, was a prospective effort to characterize germline variants in patients with advanced kidney cancer. And it's something that we talk about a lot in the kidney cancer literature, whether or not we're missing a lot of these so-called hereditary patterns of RCC. Can you tell us a little bit about that study too? Dr. Atul Batra: Yeah, so that was led by one of our fellows, Chitrakshi Nagpal, and she's just completed her fellowship. And two years back we published that. So, that was done in almost 160 consecutive patients that we recruited over the span of just one year and we saw, apart from the common known mutations in RCC, that was around 5% or so, but a lot of other mutations were also seen that we don't generally see in kidney cancers and we see in other cancers like BRCA1, BRCA2 and others. We are still, I mean, doing those analyses to see whether we get more things out of there in the somatic: is there a loss of heterozygosity or was it just present and in there? Dr. Monty Pal: I thought it was a terrific study and again, I was just so blown away at the pace. I mean, as I look at 140 patients accrued over a span of one year, this is something that would take us perhaps three times as long at City of Hope, and that's with a very sort of, what I consider to be large and dedicated kidney cancer program. So, it really underscores, I think, the need for collaboration. And ever since I came back from my visit to you at AIIMS Delhi, I think I've just been sort of transformed in the sense of trying to think of better ways for us to collaborate. One tangible thing that I'm going to get cracking on is seeing whether or not perhaps we can form some partnerships through SWOG or what we call the NCTN, the National Clinical Trials Network here within the U.S. Talk to me about collaboration. I mean, you've been really terrific at this. How do you sort of envision collaboration enhancing the global landscape of oncology? Dr. Atul Batra: That's really amazing, Monty. That's what we need. We have the infrastructure, we have the manpower, we have patients. I mean, these are all high-volume centers. Unfortunately, we are a little less in numbers, so we are more clinically occupied as well. So, sometimes it's kind of tougher, but again, when it comes to helping out the patients, global collaboration, we need to kind of take you guys along with us and have our patients finish trials earlier. This is a win-win situation for patients, one, because they also get exposure or an option to participate in the clinical trials, and second, we can answer all these scientific questions that we have at a much faster pace. All those things can be done within a much shorter span of time for sure. We are so happy to hear that, and with open hands we are ready to collaborate for all these efforts. Dr. Monty Pal: That's awesome. You know, I came back thinking, gosh, this would be so ideal for some of these rare subtypes of kidney cancer. Prospective clinical trials that I'm running in that space where really we're threatened with closure all the time. And if we just sort of extended a hand to, you know, our partners in India and other countries, you know, I'm sure we could get this research done in a meaningful way and that's got to be a win for patients. Atul, I had such a terrific time chatting with you today. I'm looking forward to seeing lots more productivity from your group there. By the way, for our viewership here, take a look and see what AIIMS New Delhi is doing under the leadership of Dr. Batra and others. It is just a real powerhouse and I think that after doing so, you'll be enticed to collaborate as well.  I'm hoping this is the first of many times that we have you on the podcast. Thank you so much for joining. Dr. Atul Batra: Thank you so much for having me here, Monty. It was a pleasure as always speaking to you. And thank you again. Dr. Monty Pal: You got it.  Well, and thanks to our listeners. I encourage you to check out Dr. Batra's paper. We'll actually have a link to the study in the transcript of this episode.  Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:     Dr. Monty Pal   @montypal Dr. Atul Batra @batraatulonc Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Atul Batra: Stock and Other Ownership Interests: Zydus Pharmaceuticals, Glenmark, Caplin Point Laboratories, Laurus Research Funding: AstraZeneca, Astellas Pharma, Alkem Laboratories

In Episode 2 of The Booked & Paid Speaker Blueprint, Sean continues building the foundation of a successful speaking business by breaking down the speaker marketing toolkit event planners actually look for. Most speakers waste time building assets that do not get them booked. In this episode, Sean explains why you do not need a one sheet and what you must have instead if you want consistent paid speaking opportunities. If you want to get booked and paid to speak consistently, your website and speaker reel are two of the most important assets you can build. In this episode, you will learn: Why event planners want to see video instead of a one sheet What every professional speaker website must include How to structure your keynote descriptions and speaker pages Why key takeaways matter more than hype or motivation How to position your talks around problems you solve What event planners actually look for before hiring a speaker How to present your experience, clients, and credibility How to create a speaking experience instead of just giving a talk

On this episode of the Hayek Program Podcast, Chris Coyne delivers a keynote lecture at the 2023 Markets & Society conference on the foundations of peace. He contrasts “top-down” peacemaking driven by elites with “bottom-up” peacemaking that emerges from the everyday practices of ordinary people.Coyne argues that much of the social-scientific and policy conversation treats peace as a public good best supplied through state-intervention. He develops an alternative framework—pax hominem—that treats peace as an emergent, learned, and constantly renewed process. Drawing on mainline political economy and the work of Kenneth Boulding, Coyne shows how peaceful cooperation depends on local knowledge, social norms, and institutions that help people navigate conflict without violence across families, communities, and markets. Together, these insights point toward a research and policy agenda focused less on imposing order and more on creating space for self-governance and the bottom-up cultivation of peace.Dr. Christopher J. Coyne is Associate Director of the F.A. Hayek Program for Advanced Study in Philosophy, Politics, and Economics at the Mercatus Center and Professor of Economics at George Mason University. He has published numerous books, including How to Run Wars: A Confidential Playbook for the National Security Elite (Independent Institute, 2024), In Search of Monsters to Destroy: The Folly of American Empire and the Paths to Peace (Independent Institute, 2022), and Doing Bad by Doing Good: Why Humanitarian Action Fails (Stanford University Press, 2013).**This episode was recorded October 20, 2024.Show Notes:Kenneth Boulding's book, Stable Peace (University of Texas Press, 1978)Elise Boulding's book, Cultures of Peace(Syracuse University Press, 2000)James C. Scott's book, Seeing Like a State (Yale University Press, 1999)Caroline Elkin's book, Legacy of Violence: A History of the British Empire (Penguin Random House, 2023)James M. Buchanan's Nobel Prize LectureElinor Ostrom et. al's paper, “Covenants with and without a Sword: Self-Governance Is Possible” (APSR, 2013)Virgil storr et. al's book, Community Revival in the Wake of Disaster: Lessons in Local Entrepreneurship (Palgrave Macmillan, 2015)Mikayla Novak's book, Freedom in Contention: Social Movements and Liberal Political Economy (Bloomsbury Publishing, 2021)Virgil Storr and Ginny Choi's book, Do Markets Corrupt Our Morals? (Palgrave Macmillan, 2019)If you like the show, please subscribe, leave a 5-star review, and tell others about the show! We're available on Apple Podcasts, Spotify, Amazon Music, and wherever you get your podcasts.Check out our other podcast from the Hayek Program! Virtual Sentiments is a podcast in which political theorist Kristen Collins interviews scholars and practitioners grappling with pressing problems in political economy with an eye to the past. Subscribe today!Follow the Hayek Program on Twitter: @HayekProgramFollow the Mercatus Center on Twitter: @mercatusCC Music: Twisterium

Hall of Fame speaker Don Yaeger joins Thom Singer for the first Speakernomics episode of 2026, sharing actionable insights on building a lasting career and business in professional speaking. Get straight to the essentials with proven tips, powerful stories, and strategies for growth.* How to constantly develop fresh content to keep your talks relevant and engaging* The importance of multiple streams of income for long-term stability* Insights from writing bestselling books and leveraging them in speaking* Creating a powerful inner circle and the impact of NSA community connections* Why signature stories set great speakers apart and tips for mastering yours Become an NSA Member! https://nsaspeaker.org/join/#membership Learn more about your ad choices. Visit megaphone.fm/adchoices

HSPI Keynote Spotlight: Inside conversations with Dr. Patterson and Lennox Wildman"In this special HSPI Keynote Spotlight episode of Problem Solved, listeners are invited inside conversations with Dr. Emily Patterson and Lennox Wildman, two leaders shaping the future of healthcare systems improvement. The episode explores how technology, workflows, and people come together to drive safer, more effective care. Through practical insights and real-world examples, these thoughtful conversations highlight how industrial and systems engineering principles are being applied to strengthen healthcare delivery and support the professionals who make it possible. Don't miss the full keynotes talks from these professionals at the HSPI Conference sponsored by Society for Health Systems!Learn more about The Institute of Industrial and Systems Engineers (IISE)Problem Solved on LinkedInProblem Solved on YouTubeProblem Solved on InstagramProblem Solved on TikTokProblem Solved Executive Producer: Elizabeth GrimesInterested in contributing to the podcast or sponsoring an episode? Email egrimes@iise.org

Dr. Joshua Reuss is back on the podcast to discuss the full update to the living guideline on stage IV NSCLC without driver alterations. He discusses the new evidence and how this impacts the latest recommendations on first-line and subsequent therapeutic options. Dr. Reuss emphasizes the need for shared decision-making between clinicians and patients. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02825    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It is great to have you back on the show today, Dr. Reuss. Dr. Joshua Reuss: Happy to be here, Brittany. Brittany Harvey: Just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer without driver alterations is updated on an ongoing basis. So, what prompted this latest update to the recommendations? Dr. Joshua Reuss: Our committee is tasked with making routine updates to the living guidelines and really keeping them living, right? So, evaluating new data as it is coming in to see, is this practice changing? Is this data that should inform and potentially alter our guideline recommendations so that practitioners and other care providers could really make the best treatment decisions for their patients? So that is something that happens on a more routine basis, but periodically, we are tasked with performing a more comprehensive update of our guideline where we really evaluate every one of our point recommendations, the data associated with these recommendations, to be sure that these are up to date, these are comprehensive, and to see if we need to alter anything in the language of these updates. Brittany Harvey: Excellent. Thank you for providing that background. And yes, this is truly a comprehensive update that goes through all the latest literature. Given that, I would like to review what has changed and what is new in the recommendations. So, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: So there are two main guidelines that we recommend from this panel. One is a driver mutation-positive guideline and the other is a driver mutation-negative guideline. And I think on first blush, one might look at kind of the recent flurry of approvals and new data and say, well, all the excitement, you know, is in the driver mutation-positive guideline. But I would say that the driver mutation-negative guideline is equally as important and really has several unique challenges associated with it. You know, first and foremost is that there are really a multitude of regimens that can be considered for any one patient. And how to choose between one can be quite difficult and a stressful challenge that clinicians can have, particularly since there are really no randomized studies comparing these regimens in a head-to-head fashion. In addition, you know, these guidelines are really broken down by two key factors. One is disease histology, so namely squamous versus non-squamous histology. And the other is PD-L1 status, broken down into one of three tertiles: PD-L1 high, which is greater than or equal to 50% expression; PD-L1 low, which is 1% to 49% expression; and then PD-L1 negative or unknown. So what you are really looking at, if you do that math, is really six unique patient subpopulations where we need to make a recommendation on one of the multitude of treatment regimens that is approved. And what that means is you are oftentimes really looking at subset and sub-subset level data to help inform clinicians in their treatment decision making, which can be quite challenging because as those small subsets of data is more and more parsed, there are many confounders that can be interjected there. And so I think the committee is tasked with really quite a challenge in terms of how to really communicate and broadcast that data in a way that informs clinicians in making a decision on what is the right treatment for their patient. Brittany Harvey: Absolutely. It can be challenging to interpret that subgroup data across several different studies that are reporting on different regimens and different outcomes. And I appreciate you mentioning the driver mutation-positive guideline as well. Listeners can check out the companion episode with Dr. Puri for more information on what is changed in the driver mutation-positive guideline. Based on that primer, what is new for first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: Even though I will say there is not a lot of new trial data that was incorporated into this guideline, there were some updates and just some meaningful long-term data that we incorporated. I think first and foremost, there is a new top-level recommendation in this guideline pertaining to molecular testing, which is absolutely critical in both the driver mutation-positive and driver mutation-negative space. I think we tend to think that, oh, well, molecular testing really only pertains to then finding a driver mutation. But the lack of a mutation is absolutely critical as well, right? Because that is what leads us down the mutation-negative pathway. We also need this molecular testing to assess PD-L1 status. We are seeing emerging data on molecular mutations that might confer resistance to certain immunotherapy-based strategies. So the committee felt strongly that a recommendation on molecular testing is critical to include in both the driver mutation-positive guideline and the driver mutation-negative guideline. I will also say that we are now seeing five and six-year updates from some of the landmark trials of immunotherapy in driver mutation-negative non-small cell lung cancer. It is really incredible to see that in some of these trials, we are seeing very impressive durability of the treatment in the patient subsets that we are commenting on. In others, perhaps that durability is less clear, and I think that leads to challenges in making a recommendation on any one particular regimen. And I think that is nowhere more clear than in the squamous subset. I think that was one perhaps subtle change that is in this guideline where, particularly in the PD-L1 negative squamous population, the committee felt that no one regimen really was worthy of standing above the others. Sometimes I think it is important to really champion one unique regimen if we feel that the data is there to support it. But I think it is equally important to list multiple regimens where the data is less clear. I think another point is that while perhaps there were no new regimens that we have added or that led to other clear changes in the prioritization of one regimen over another, there are other unique data subsets that I think come into play in making a decision and that really are important when looking at the discussion on any one recommendation from this guideline. For example, we know there is emerging data on perhaps the significance of molecular alterations in KEAP1 or STK11 and how that might influence frontline decision-making. You know, there is not a prospective phase III trial in this population, but I think we still need to use that data in certain scenarios to make recommendations for a particular patient. Another example of a trial that, again, did not change our recommendations, but I think one can incorporate in their decision making is the KEYNOTE-598 trial. Now, this is not a new study, but what it studied was pembrolizumab versus pembrolizumab plus ipilimumab in a PD-L1 high subset, and found that the addition of ipilimumab to pembrolizumab in the PD-L1 high population did not significantly improve clinical efficacy. And so while pembrolizumab plus ipilimumab is not an approved regimen, it is hard to extrapolate that to our combination treatments that are approved. I think some clinicians might find that data valuable when making a frontline treatment decision on a patient who has PD-L1 high status. So a bit of a whirlwind tour, but I think there are still multiple factors that went into this guideline that are important to review when making treatment decisions for any one patient. Brittany Harvey: Absolutely. I think what you just mentioned in having that upfront molecular testing is really key for individualized patient care. And the evidence summaries that you provide in addition to the recommendations are really important for clinicians to be able to refer to as they are making decisions in their clinic. So then beyond those changes for first-line therapy, what is updated for second-line and subsequent therapies? Dr. Joshua Reuss: For second-line and subsequent therapies, we did see one new treatment recommendation join these ranks, and that was telisotuzumab vedotin. Telisotuzumab vedotin, quite a mouthful. That is an antibody-drug conjugate. I like to think of that as smart chemotherapy, targeted chemotherapy, where you are trying to utilize some aspect of a marker that is selectively expressed or overexpressed on the cancer surface to then shepherd in the anticancer molecule, a highly potent chemotherapeutic in the case of currently approved antibody-drug conjugates, to exert antitumor killing effect. So in this case, the antibody-drug conjugate telisotuzumab vedotin targets MET overexpression. So telisotuzumab is an antibody targeting MET, and that is conjugated to an MMAE highly potent chemotherapeutic payload called vedotin. So we know MET can be selectively expressed and overexpressed in non-small cell lung cancer in both driver mutation-positive and mutation-negative subsets. The data that led to this approval was from the phase II LUMINOSITY trial which evaluated telisotuzumab vedotin, or Teliso-V, in many subsets. But the subset that really showed promise and was expanded was the EGFR wild-type, non-squamous, non-small cell lung cancer population with MET overexpression. And so in 78 patients with high levels of expression, the response rate here was 34.6%, median progression-free survival of 5.5 months, and a median overall survival of 14.6 months. With an overall acceptable safety profile; grade 3 or higher adverse events, neuropathy was perhaps the most common at 7%, also increased ALT at 3.5%, and pneumonitis at 2.9%. Now this was phase II data that led to an accelerated approval. There is an ongoing phase III study randomizing patients with high expression to Teliso-V versus docetaxel. That is the phase III TeliMET study. But it is nice that we now have another option for patients, perhaps a more biomarker-directed option with, again, this MET overexpression. And again, it further reinforces the importance of molecular testing in patients with traditionally driver mutation-negative non-small cell lung cancer, whether that is upfront or at progression, and in particular utilizing immunohistochemistry to assess MET expression in these patients. And this does join another ADC that we had previously made an update in our recommendation, which is trastuzumab deruxtecan, which is approved for those patients with HER2-overexpressing non-small cell lung cancer. So just again to reiterate the importance of molecular testing in patients both at the outset of their treatment and upon progression on frontline therapy. Brittany Harvey: Definitely. It is great to have this new antibody-drug conjugate join the treatment options, and as you mentioned, very important in this case to have that molecular testing done at the outset and at progression. So then in your view, what should clinicians know as they implement this living guideline, and how do these changes impact patients with non-small cell lung cancer? Dr. Joshua Reuss: Because there are so many different regimens that one can consider for any one patient, I think it is easy to become overwhelmed and stress on, "Am I making the right choice for my patient?" And I think one of the key take home points is that in many cases, there is no one right regimen. And I think one has to weigh several factors. It is the treatment schedule. It is the toxicity profile. It is the molecular profile of the patient. It is the patient preference. You know, there are so many factors here. And I would like to draw the reader and viewer's attention to an important section of these guidelines, particularly the Patient and Clinician Communication section, where we have a box focused on discussion points between patients and clinicians, which I think focuses on several of the high-level points that one can emphasize in making these decisions, ranging on things from: what are the goals of the treatment? What are the risks and benefits to any one approach? What are comorbidities that should be factored in? Common concerns, toxicity management, clinical trial consideration. All of these factors that I think are incredibly important in making that frontline treatment decision and implementing a regimen that both the clinician and, more importantly, the patient feels comfortable with. Brittany Harvey: It is really important that there is shared decision-making in these scenarios. And I think that patient-clinician communication section can tease out some of those preferences from the patient end and talk through the risks and benefits of different regimens as well. As we mentioned at the top of this episode, this guideline is a living guideline and updated on an ongoing basis. So what is the panel examining and keeping an eye on for future updates to this guideline? Dr. Joshua Reuss: So I think there are a lot of exciting new therapies and more up-to-date trials that we are anxiously awaiting the results of on our committee, and I think the oncology community in general is awaiting the results of. When we will have these results, I think, is a bit of an open-ended question, but I can give some insight on several of the trials that our committee is really keeping a close eye on. One that we have mentioned for several guideline iterations is the ECOG-ACRIN INSIGNA trial. This is a phase III clinical trial comparing pembrolizumab versus pembrolizumab plus carboplatin and pemetrexed chemotherapy in PD-L1 positive, non-squamous, non-small cell lung cancer. We talk about there being different regimens that can be considered in PD-L1 positive and PD-L1 high subsets, namely immunotherapy alone or immunotherapy plus chemotherapy, but there is no direct head-to-head comparison here. So this trial hopefully will answer that question. It has now finished accrual. There are other very interesting molecules and trials. I think another interesting compound is ivonescimab. This is a PD-1/VEGF bispecific antibody that is currently approved in China as monotherapy in patients with PD-L1 positive non-small cell lung cancer based off of the HARMONi-2 trial, where the progression-free survival of this bispecific antibody, ivonescimab, appeared superior to pembrolizumab. And we are looking closely at ongoing trials to see if these results will be replicated in an ex-China population. And if so, I think it could have a real impact and change on our guidelines. Still other very interesting things. There are obviously confirmatory studies for antibody-drug conjugates, such as the TeliMET study that I alluded to earlier, and many promising antibody-drug conjugates, both bispecific and trispecific antibody-drug conjugates, that hopefully can inform practice. And then there are several unique subsets of populations that I think we now are utilizing data on to make decisions, but a lot of that is retrospective in small subsets where we do not have that prospective data. And there are several trials ongoing in some of these subsets to try to gain clarity on what regimen may be the best for patients. One example is the phase III TRITON trial, which is looking at comparing CTLA-4 containing regimen, particularly the POSEIDON regimen of durvalumab plus tremelimumab and chemotherapy, versus the KEYNOTE-189 regimen, which is pembrolizumab plus carboplatin and pemetrexed, in patients with non-squamous, non-small cell lung cancer that have alterations in either KRAS, KEAP1, and/or STK11. There is a lot of both preclinical and clinical data to suggest that patients with these alterations in STK11 and KEAP1 may be more resistant to a PD-1 based treatment approach, and perhaps the incorporation of CTLA-4 can lead to a more meaningful response in this unique subset. Obviously, that data, it is retrospective, it is in small subsets. And when you add in a CTLA-4 molecule, you are also introducing greater risk for toxicity. So this trial is going to be very important in elucidating: is there a benefit in that unique subset? Does that data that we see retrospectively in this small subset hold true when evaluated in a prospective fashion? So while our guideline, our most recent comprehensive panel update, may not have had a lot of new data in it that has influenced frontline treatment decision-making, I think the future is bright and there are a lot of novel studies and novel treatments on the horizon that will hopefully improve the outcomes for our patients. Brittany Harvey: Absolutely. We will look forward to the results of those ongoing trials to provide more options and particularly clarity for patients with non-small cell lung cancer and to inform this guideline and its many updates to come. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Reuss. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

One of the most common mistakes I see speakers make is trying to deliver a six-week course or a full-length book in a 45-minute talk.And then they wonder why: • the audience looks overwhelmed • the energy drops • no one remembers their message • leads don't convertHere's the mindset shift that changes everything: Same message. Different medium. Different strategy.When your message doesn't match the format, your talk can feel confusing, overwhelming, and forgettable — no matter how good your content is. But when your message fits the medium, your impact multiplies.In this episode, I share:The reasons you want to cram more content into your presentationsHow each format — lead generation presentation, keynote, workshop, course, coaching, and book — plays a distinct roleWhy books are uniquely powerful for depth, nuance, and authority (and how this ties into my upcoming author interviews)How to escape the expert trap and step into thought leadershipIf you're building talks, presentations, workshops, courses, or a book, this episode will completely change how you think about your content ecosystem.Ready to build a signature talk that gets you the results you want? Learn more about working with us inside the Thought Leader Academy or through a stand-alone VIP Day.Links:Show notes and Message-Medium visual image at https://www.speakingyourbrand.com/458/  Discover your Speaker Archetype by taking our free quiz at https://www.speakingyourbrand.com/quiz/Enroll in our Thought Leader Academy: https://www.speakingyourbrand.com/academy/ Attend our 1-day Speaking Accelerator Workshop in Orlando: https://www.speakingyourbrand.com/orlando/ Connect on LinkedIn: https://www.linkedin.com/in/carolcoxRelated Podcast Episodes:Podcast Series: The Medium is the MessageEpisode 422: How to Create a 10-Out-of-10 Keynote that Leaves Your Audience in Awe with Julia KornEpisode 362: Integrating Thought Leadership and Lead Generation in Your Signature Talk with Danielle HaydenEpisode 257: Writing a Book Gives Your Ideas Depth and Longevity with Tiffany Hawk

On this week's episode of The MacRumors Show, we discuss Apple's newly launched AirTag 2 and Apple Creator Studio.Earlier this week, Apple announced the second-generation ‌AirTag‌, marking the first major update to its item tracker since the product's introduction in 2021, with improvements focused on tracking range, audio output, and device support rather than changes to its physical design.The new ‌AirTag‌ uses a second-generation Ultra Wideband chip that extends Precision Finding range by up to 50%, adds support for Precision Finding on compatible Apple Watch models for the first time, and includes an upgraded Bluetooth specification designed to improve general tracking range. Apple also says the built-in speaker is up to 50% louder, making it easier to locate items in noisy environments.Externally, the ‌AirTag‌ remains visually similar to the original and continues to use a replaceable CR2032 coin battery with more than a year of battery life, while internally Apple has made a significant number of internal changes. The second-generation ‌AirTag‌ is priced the same as before at $29 for a single unit or $99 for a four-pack, is compatible with existing ‌AirTag‌ accessories, and requires devices running iOS 26.2.1 or later.Apple also launched Creator Studio, a new all-in-one subscription aimed at content creators. For $12.99 per month, or $129 per year, Creator Studio provides access to Final Cut Pro, Logic Pro, Pixelmator Pro, Motion, Compressor, and MainStage, consolidating tools for video editing, music production, image editing, and live performance. The bundle replaces Apple's long-standing one-time purchase model for these apps with a subscription approach, while keeping standalone versions available for users who do not want access to the full package.Beyond bundling existing apps, Creator Studio introduces a set of AI-powered features that are exclusive to subscribers. These include transcript and visual search in Final Cut Pro, enhanced beat detection and new dynamic titles, AI-assisted session players and harmonic analysis in Logic Pro, and new design and warp tools in Pixelmator Pro, which is now available on iPad for the first time. The subscription also unlocks premium AI features in Apple's free productivity apps, including Keynote, Pages, and Numbers, with Freeform support coming later.Creator Studio is available now via the App Store, with a one-month free trial for all users and a three-month trial for customers who purchase a qualifying new Mac or ‌iPad‌. The subscription supports Family Sharing for up to six people, includes discounted pricing for students and educators.

We all know Siri can be frustrating, but Dave has a story about shoveling snow and trying to use Siri at the same time that had me laughing. I probably should feel bad about it, but it was just too good. More news from Mark Gurman this week on Apple's plans to run their AI efforts using Google's Gemini. Brought to you by: Copilot Money: For a limited-time, when you sign up at copilot.money (new users only, web only) you can get two months free with code DALRYMPLE. Start the new year with clarity. Your money, beautifully organized, now across every device. Show Notes: Apple reportedly replacing Siri interface with actual chatbot experience for iOS 27 Gurman on Apple's AI Sebastiaan de With joins design team at Apple Apple introduces new AirTag with expanded range and improved findability Apple's 'Creator Studio' App Bundle Now Available for $12.99 Per Month Apple Updates Keynote, Numbers, and Pages Apps With New Free and Paid Features Should you update to the new Pages, Numbers, Keynote, and Freeform on Mac? Search Your Apple Account Purchase History on iPhone Apple turning to Intel for future iPhone chips, analyst reaffirms Shows and movies we're watching Prime Target, Apple TV Springsteen: Deliver Me from Nowhere, Disney+

Benjamin and Chance review the proposition of the Creator Studio bundle now it is finally available, as well as some weirdness in the choices made of the apps in it. Also, Benjamin has been using his new AirTags for the past couple days, and Bloomberg's Mark Gurman suggests that the new Gemini Siri features may be announced in February, sooner than we previously expected. And in Happy Hour Plus, there's more talk about Creator Studio, specifically regarding which other kinds of creative apps we could see get added to the offering in the future. Join now and save 26% on annual plans with code HAPPY26. Last call! Sponsored by Quince: Refresh your winter wardrobe with Quince. Visit quince.com/happyhour for free shipping on your order and 365-day returns. Sponsored by Shopify: In 2026, stop waiting and start selling with Shopify. Sign up for a $1 per month trial at shopify.com/happyhour. Sponsored by Copilot Money: Get two months free with code 9TO5Mac at try.copilot.money/9to5mac. Hosts Chance Miller @ChanceHMiller on Twitter @ChanceHMiller on Instagram @ChanceHMiller on Threads Benjamin Mayo @bzamayo on Twitter @bzamayo@mastodon.social @bzamayo on Threads Subscribe, Rate, and Review Apple Podcasts Overcast Spotify 9to5Mac Happy Hour Plus Subscribe to 9to5Mac Happy Hour Plus! Support Benjamin and Chance directly with Happy Hour Plus! 9to5Mac Happy Hour Plus includes:  Ad-free versions of every episode  Pre- and post-show content Bonus episodes Join for $5 per month or $50 a year at 9to5mac.com/join.  Feedback Submit #Ask9to5Mac questions on Twitter, Mastodon, or Threads Email us feedback and questions to happyhour@9to5mac.com Links Apple Creator Studio launches today, and it's an incredible value Stephen Robles: Apple Creator Studio Pages, Keynote, Numbers get iOS 26 updates, here's everything new AirTag 2 vs AirTag: Here's everything new AirTag 2 teardown reveals the speaker is now harder to remove AirTag 2 hands-on review: Apple's clever item tracker finds even more utility with longer range and louder sound How to tell the difference between AirTag 2 and the original AirTag AirTag 2: Three tidbits you might have missed Apple to 'unveil' results of Google Gemini partnership as soon as next month: report Apple announces new Black Unity Braided Solo Loop for Apple Watch iOS 26.3 adds new feature to limit location data shared with your carrier

View this video at https://macmost.com/live-exploring-apple-creator-studio.html. Join me as a look at the various new features you get with Apple Creator Studio, with an emphasis on Mac Pages, Numbers, Keynote and Pixelmator Pro.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Shelby Williams.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Shelby Williams.